Oculis starts Phase 3 in Diabetic Macular Edema

 

• DIAMOND-1 Phase 3 trial, assessing the efficacy and safety of OCS-01 eye drops following 52 weeks of treatment in Diabetic Macular Edema (DME) patients, was initiated as planned
  
• Stage 1 results showed superiority of OCS-01 eye drops vs. vehicle with robust statistical significance with no unexpected adverse events observed
  
• Second 52 weeks Phase 3 trial of OCS-01 in DME, DIAMOND-2, is anticipated to start in Q1 2024
  
• If approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME

https://www.globenewswire.com/news-release/2023/12/18/2797627/0/en/Oculis-Announces-First-Patient-First-Visit-in-Phase-3-DIAMOND-1-Trial-of-OCS-01-Eye-Drop-in-Diabetic-Macular-Edema.html